| Filed | Form | Description | |
|---|---|---|---|
| 2/9/24 | DEFA14A | DEFA14A | → |
| 1/18/24 | DEFM14A | DEFM14A | → |
| 1/5/24 | PREM14A | PREM14A | → |
| 12/7/23 | DEFA14A | DEFA14A | → |
| 4/28/23 | DEFA14A | DEFA14A | → |
| 4/28/23 | DEF 14A | DEF 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 8/5/24 | 4 | PRIMARY DOCUMENT | → |
| 8/5/24 | SC 13D/A | SC 13D/A CEREVEL THERAPEUTICS HOLDINGS 5 | → |
| 8/5/24 | 4 | 4 | → |
| 8/5/24 | 4 | 4 | → |
| 8/5/24 | 4 | 4 | → |
| 8/5/24 | 4 | 4 | → |
| ↓ | |||
Cerevel Therapeutics Holdings, Inc. was an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.